Hiroki Junko, Shimokawa Hiroaki, Higashi Midoriko, Morikawa Keiko, Kandabashi Tadashi, Kawamura Natsumi, Kubota Toru, Ichiki Toshihiro, Amano Mutsuki, Kaibuchi Kozo, Takeshita Akira
Department of Cardiovascular Medicine, and the 21st Century COE Program on Lifestyle-Related Diseases, Kyushu University Graduate School of Medical Sciences, 3-1-1 Maldashi, Higashi-ku, Fukuoka 812-8582, Japan.
J Mol Cell Cardiol. 2004 Aug;37(2):537-46. doi: 10.1016/j.yjmcc.2004.05.008.
Recent studies have demonstrated that upregulated Rho-kinase plays an important role in the pathogenesis of arteriosclerosis and vasospasm in both animals and humans. However, little is known about the molecular mechanism(s) involved in the Rho-kinase upregulation. Since inflammatory mechanisms have been implicated in the pathogenesis of arteriosclerosis and vasospasm, we examined whether inflammatory stimuli upregulate Rho-kinase in vitro and in vivo. In cultured human coronary vascular smooth muscle cells (hcVSMC), inflammatory stimuli, such as angiotensin II and interleukin-1beta, increased Rho-kinase expression (at both mRNA and protein levels) and function (as evaluated by the extent of the phosphorylation of the ERM (the ezrin/radixin/moesin) family, substrates of Rho-kinase) in a time- and concentration-dependent manner. The expression of Rho-kinase was inhibited by blockades of protein kinase C (PKC) (by either GF109253 or prolonged treatment with phorbol myristate acetate for 24 h) and an adenovirus-mediated gene transfer of dominant-active Ikappa-B, suggesting an involvement of PKC and NF-kappaB in the intracellular signal transduction pathway for the Rho-kinase expression. Furthermore, coronary vascular lesion formation (characterized by medial thickening and perivascular fibrosis) induced by a long-term administration of angiotensin II was markedly suppressed in NF-kappaB(-/-) mice with reduced expression and activity of Rho-kinase in vivo. These results indicate that the expression and function of Rho-kinase are upregulated by inflammatory stimuli (e.g. angiotensin II and IL-1beta) in hcVSMC with an involvement of PKC and NF-kappaB both in vitro and in vivo.
最近的研究表明,Rho激酶上调在动物和人类的动脉粥样硬化及血管痉挛发病机制中起重要作用。然而,关于Rho激酶上调所涉及的分子机制却知之甚少。由于炎症机制已被认为与动脉粥样硬化和血管痉挛的发病机制有关,我们研究了炎症刺激在体外和体内是否会上调Rho激酶。在培养的人冠状动脉血管平滑肌细胞(hcVSMC)中,炎症刺激,如血管紧张素II和白细胞介素-1β,以时间和浓度依赖的方式增加了Rho激酶的表达(在mRNA和蛋白质水平)和功能(通过Rho激酶底物ERM(埃兹蛋白/根蛋白/莫伊塞恩)家族的磷酸化程度来评估)。蛋白激酶C(PKC)的阻断剂(通过GF109253或用佛波酯肉豆蔻酸酯乙酸盐延长处理24小时)以及腺病毒介导的显性活性Ikappa-B基因转移抑制了Rho激酶的表达,这表明PKC和NF-kappaB参与了Rho激酶表达的细胞内信号转导途径。此外,在体内Rho激酶表达和活性降低的NF-kappaB(-/-)小鼠中,长期给予血管紧张素II诱导的冠状动脉血管病变形成(以内膜增厚和血管周围纤维化为特征)明显受到抑制。这些结果表明,在hcVSMC中,炎症刺激(如血管紧张素II和IL-1β)上调了Rho激酶的表达和功能,且在体外和体内PKC和NF-kappaB均参与其中。